Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Thomas Corbett

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Living Beings

Chemicals & Drugs

Procedures

Disorders

Anatomy

Cultured Tumor Cells

Concepts & Ideas

Structure-Activity Relationship

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
29
Polin , Lisa Anne
19
Valeriote, Frederick
15
LoRusso, Patricia
14
Horwitz, Jerome
14
White, Kathryn
12
Kushner, Juiwanna
9
Moore, Richard
8
Pugh, Susan
8
Bissery, MC
7
Baker, Laurence
7
Rake, JB
7
Hazeldine, Stuart
6
Leopold, Wilbur
6
Foster, Brenda
6
Heilbrun, Lance

Sign-in to see all Coauthors

Publications

TOP 3
Hazeldine Stuart T; Polin Lisa; Kushner Juiwanna; White Kathryn; Corbett Thomas H; Horwitz Jerome P
Synthesis and biological evaluation of conformationally constrained analogs of the antitumor agents XK469 and SH80. Part 5.
Hazeldine Stuart T; Polin Lisa; Kushner Juiwanna; White Kathryn; Corbett Thomas H; Horwitz Jerome P
Synthetic modification of the 2-oxypropionic acid moiety in 2-{4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy}propionic acid (XK469), and consequent antitumor effects. Part 4.
Liang Jian; Moore Richard E; Moher Eric D; Munroe John E; Al-awar Rima S; Hay David A; Varie David L; Zhang Tony Y; Aikins James A; Martinelli Michael J; Shih Chuan; Ray James E; Gibson Lowell L; Vasudevan Vasu; Polin Lisa; White Kathryn; Kushner Juiwanna; Simpson Chiab; Pugh Susan; Corbett Thomas H
Cryptophycins-309, 249 and other cryptophycin analogs: preclinical efficacy studies with mouse and human tumors.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Thomas Corbett (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2006: Hazeldine Stuart T; Polin Lisa; Kushner Juiwanna; White Kathryn; Corbett Thomas H; Horwitz Jerome P
Synthesis and biological evaluation of conformationally constrained analogs of the antitumor agents XK469 and SH80. Part 5.
Bioorganic & medicinal chemistry 2006;14(7):2462-7.
2005: Hazeldine Stuart T; Polin Lisa; Kushner Juiwanna; White Kathryn; Corbett Thomas H; Horwitz Jerome P
Synthetic modification of the 2-oxypropionic acid moiety in 2-{4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy}propionic acid (XK469), and consequent antitumor effects. Part 4.
Bioorganic & medicinal chemistry 2005;13(12):3910-20.
2005: Liang Jian; Moore Richard E; Moher Eric D; Munroe John E; Al-awar Rima S; Hay David A; Varie David L; Zhang Tony Y; Aikins James A; Martinelli Michael J; Shih Chuan; Ray James E; Gibson Lowell L; Vasudevan Vasu; Polin Lisa; White Kathryn; Kushner Juiwanna; Simpson Chiab; Pugh Susan; Corbett Thomas H
Cryptophycins-309, 249 and other cryptophycin analogs: preclinical efficacy studies with mouse and human tumors.
Investigational new drugs 2005;23(3):213-24.
2005: Hazeldine Stuart T; Polin Lisa; Kushner Juiwanna; White Kathryn; Corbett Thomas H; Biehl Jason; Horwitz Jerome P
Part 3: synthesis and biological evaluation of some analogs of the antitumor agents, 2-{4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy}propionic acid, and 2-{4-[(7-bromo-2-quinolinyl)oxy]phenoxy}propionic acid.
Bioorganic & medicinal chemistry 2005;13(4):1069-81.
2004: Al-Awar Rima S; Corbett Thomas H; Ray James E; Polin Lisa; Kennedy Joseph H; Wagner Margaret M; Williams Daniel C
Biological evaluation of cryptophycin 52 fragment A analogues: effect of the multidrug resistance ATP binding cassette transporters on antitumor activity.
Molecular cancer therapeutics 2004;3(9):1061-7.
2004: Evelhoch Jeffrey L; LoRusso Patricia M; He Zhanquan; DelProposto Zachary; Polin Lisa; Corbett Thomas H; Langmuir Peter; Wheeler Catherine; Stone Andrew; Leadbetter Joanna; Ryan Anderson J; Blakey David C; Waterton John C
Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(11):3650-7.
2003: Zhang Yuxiang; Dawson Marcia I; Ning Yangmin; Polin Lisa; Parchment Ralph E; Corbett Thomas; Mohamed Anwar N; Feng Kai-Chia; Farhana Lulu; Rishi Arun K; Hogge Donna; Leid Mark; Peterson Valerie J; Zhang Xiao-kun; Mohammad Ramzi; Lu Jing-Song; Willman Cheryl; VanBuren Eric; Biggar Sandra; Edelstein Mark; Eilender David; Fontana Joseph A
Induction of apoptosis in retinoid-refractory acute myelogenous leukemia by a novel AHPN analog.
Blood 2003;102(10):3743-52.
2003: Al-Awar Rima S; Ray James E; Schultz Richard M; Andis Sherri L; Kennedy Joseph H; Moore Richard E; Liang Jian; Golakoti Trimurtulu; Subbaraju Gottumukkala V; Corbett Thomas H
A convergent approach to cryptophycin 52 analogues: synthesis and biological evaluation of a novel series of fragment a epoxides and chlorohydrins.
Journal of medicinal chemistry 2003;46(14):2985-3007.
2003: Boinpally Ramesh R; Polin Lisa; Zhou Sen-Lin; Jasti Bhaskara R; Wiegand Richard A; White Kathryn; Kushner Juiwanna; Horwitz Jerome P; Corbett Thomas H; Parchment Ralph E
Pharmacokinetics and tissue distribution of cryptophycin 52 (C-52) epoxide and cryptophycin 55 (C-55) chlorohydrin in mice with subcutaneous tumors.
Cancer chemotherapy and pharmacology 2003;52(1):25-33.
2003: Mooberry Susan L; Leal Rachel M; Tinley Tina L; Luesch Hendrik; Moore Richard E; Corbett Thomas H
The molecular pharmacology of symplostatin 1: a new antimitotic dolastatin 10 analog.
International journal of cancer. Journal international du cancer 2003;104(4):512-21.
2003: Corbett Thomas H; White Kathryn; Polin Lisa; Kushner Juiwanna; Paluch Jennifer; Shih Chuan; Grossman Cora Sue
Discovery and preclinical antitumor efficacy evaluations of LY32262 and LY33169.
Investigational new drugs 2003;21(1):33-45.
2002: Wang Ruifang; Corbett Thomas H; Cheng Yung-Chi; Drach John C; Kern Earl R; Mitsuya Hiroaki; Zemlicka Jiri
Tryptophanyl phosphoramidates as prodrugs of synadenol and its E-isomer: synthesis and biological activity.
Bioorganic & medicinal chemistry letters 2002;12(17):2467-70.
2002: Hazeldine Stuart T; Polin Lisa; Kushner Juiwanna; White Kathryn; Bouregeois Nicole M; Crantz Brianna; Palomino Eduardo; Corbett Thomas H; Horwitz Jerome P
II. Synthesis and biological evaluation of some bioisosteres and congeners of the antitumor agent, 2-(4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy)propionic acid (XK469).
Journal of medicinal chemistry 2002;45(14):3130-7.
2002: Poondru Srinivasu; Parchment Ralph E; Purohit Vivek; LoRusso Patricia; Horwitz Jerome P; Hazeldine Stuart T; Polin Lisa; Corbett Thomas; Jasti Bhaskara R
Lack of in vitro-in vivo correlation of a novel investigational anticancer agent, SH 30.
Investigational new drugs 2002;20(1):23-33.
2002: Polin Lisa; White Kathryn; Kushner Juiwanna; Paluch Jennifer; Simpson Chiab; Pugh Susan; Edelstein Matthew K; Hazeldine Stuart; Fontana Joseph; LoRusso Patricia; Horwitz Jerome P; Corbett Thomas H
Preclinical efficacy evaluations of XK-469: dose schedule, route and cross-resistance behavior in tumor bearing mice.
Investigational new drugs 2002;20(1):13-22.
2002: Luesch Hendrik; Yoshida Wesley Y; Moore Richard E; Paul Valerie J; Mooberry Susan L; Corbett Thomas H
Symplostatin 3, a new dolastatin 10 analogue from the marine cyanobacterium Symploca sp. VP452.
Journal of natural products 2002;65(1):16-20.
2001: Wang R; Ksebati M B; Corbett T H; Kern E R; Drach J C; Zemlicka J
Methylene-gem-difluorocyclopropane analogues of nucleosides: synthesis, cyclopropene-methylenecyclopropane rearrangement, and biological activity.
Journal of medicinal chemistry 2001;44(23):4019-22.
2001: Poondru S; Zhou S; Rake J; Shackleton G; Corbett T H; Parchment R E; Jasti B R
High-performance liquid chromatographic method for the estimation of the novel investigational anti-cancer agent SR271425 and its metabolites in mouse plasma.
Journal of chromatography. B, Biomedical sciences and applications 2001;759(1):175-8.
2001: Luesch H; Moore R E; Paul V J; Mooberry S L; Corbett T H
Isolation of dolastatin 10 from the marine cyanobacterium Symploca species VP642 and total stereochemistry and biological evaluation of its analogue symplostatin 1.
Journal of natural products 2001;64(7):907-10.
2001: Luesch H; Yoshida W Y; Moore R E; Paul V J; Corbett T H
Total structure determination of apratoxin A, a potent novel cytotoxin from the marine cyanobacterium Lyngbya majuscula.
Journal of the American Chemical Society 2001;123(23):5418-23.
2001: Hazeldine S T; Polin L; Kushner J; Paluch J; White K; Edelstein M; Palomino E; Corbett T H; Horwitz J P
Design, synthesis, and biological evaluation of analogues of the antitumor agent, 2-(4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy)propionic acid (XK469).
Journal of medicinal chemistry 2001;44(11):1758-76.
2000: LoRusso P M; Foster B J; Wozniak A; Heilbrun L K; McCormick J I; Ruble P E; Graham M A; Purvis J; Rake J; Drozd M; Lockwood G F; Corbett T H
Phase I pharmacokinetic study of the novel antitumor agent SR233377.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(8):3088-94.
1999: Varie D L; Shih C; Hay D A; Andis S L; Corbett T H; Gossett L S; Janisse S K; Martinelli M J; Moher E D; Schultz R M; Toth J E
Synthesis and biological evaluation of cryptophycin analogs with substitution at C-6 (fragment C region).
Bioorganic & medicinal chemistry letters 1999;9(3):369-74.
1999: Shih C; Gossett L S; Gruber J M; Grossman C S; Andis S L; Schultz R M; Worzalla J F; Corbett T H; Metz J T
Synthesis and biological evaluation of novel cryptophycin analogs with modification in the beta-alanine region.
Bioorganic & medicinal chemistry letters 1999;9(1):69-74.
1999: Corbett T H; Panchapor C; Polin L; Lowichik N; Pugh S; White K; Kushner J; Meyer J; Czarnecki J; Chinnukroh S; Edelstein M; LoRusso P; Heilbrun L; Horwitz J P; Grieshaber C; Perni R; Wentland M; Coughlin S; Elenbaas S; Philion R; Rake J
Preclinical efficacy of thioxanthone SR271425 against transplanted solid tumors of mouse and human origin.
Investigational new drugs 1999;17(1):17-27.
1998: Harrigan G G; Yoshida W Y; Moore R E; Nagle D G; Park P U; Biggs J; Paul V J; Mooberry S L; Corbett T H; Valeriote F A
Isolation, structure determination, and biological activity of dolastatin 12 and lyngbyastatin 1 from Lyngbya majuscula/Schizothrix calcicola cyanobacterial assemblages.
Journal of natural products 1998;61(10):1221-5.
1998: Harrigan G G; Luesch H; Yoshida W Y; Moore R E; Nagle D G; Paul V J; Mooberry S L; Corbett T H; Valeriote F A
Symplostatin 1: A dolastatin 10 analogue from the marine cyanobacterium Symploca hydnoides.
Journal of natural products 1998;61(9):1075-7.
1998: Perni R B; Wentland M P; Huang J I; Powles R G; Aldous S; Klingbeil K M; Peverly A D; Robinson R G; Corbett T H; Jones J L; Mattes K C; Rake J B; Coughlin S A
Synthesis and antitumor activity of 4-aminomethylthioxanthenone and 5-aminomethylbenzothiopyranoindazole derivatives.
Journal of medicinal chemistry 1998;41(19):3645-54.
1998: Sperry S; Valeriote F A; Corbett T H; Crews P
Isolation and cytotoxic evaluation of marine sponge-derived norterpene peroxides.
Journal of natural products 1998;61(2):241-7.
1998: LoRusso P M; Parchment R; Demchik L; Knight J; Polin L; Dzubow J; Behrens C; Harrison B; Trainor G; Corbett T H
Preclinical antitumor activity of XK469 (NSC 656889).
Investigational new drugs 1998;16(4):287-96.
1998: Corbett T H; LoRusso P; Demchick L; Simpson C; Pugh S; White K; Kushner J; Polin L; Meyer J; Czarnecki J; Heilbrun L; Horwitz J P; Gross J L; Behrens C H; Harrison B A; McRipley R J; Trainor G
Preclinical antitumor efficacy of analogs of XK469: sodium-(2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]propionate.
Investigational new drugs 1998;16(2):129-39.
1998: Valeriote F A; Corbett T H; Grieco P A; Moher E D; Collins J L; Fleck T J
Anticancer activity of glaucarubinone analogues.
Oncology research 1998;10(4):201-8.
1998: Edelstein M; Corbett T; Valeriote F
In vitro screening model for the detection of agents active against myelogenous leukemia.
Cancer investigation 1998;16(5):303-8.
1997: Foster B J; Wiegand R A; Pugh S; LoRusso P M; Rake J; Corbett T H
Pharmacokinetic studies in mice of two new thioxanthenones (183577 and 232759) that showed preferential solid tumor activity.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(11):2047-53.
1997: Corbett T H; Valeriote F A; Demchik L; Lowichik N; Polin L; Panchapor C; Pugh S; White K; Kushner J; Rake J; Wentland M; Golakoti T; Hetzel C; Ogino J; Patterson G; Moore R
Discovery of cryptophycin-1 and BCN-183577: examples of strategies and problems in the detection of antitumor activity in mice.
Investigational new drugs 1997;15(3):207-18.
1997: Foster B J; Jones L; Wiegand R; LoRusso P M; Corbett T H
Preclinical pharmacokinetic, antitumor and toxicity studies with CI-994 (correction of CL-994) (N-acetyldinaline).
Investigational new drugs 1997;15(3):187-94.
1997: Polin L; Valeriote F; White K; Panchapor C; Pugh S; Knight J; LoRusso P; Hussain M; Liversidge E; Peltier N; Golakoti T; Patterson G; Moore R; Corbett T H
Treatment of human prostate tumors PC-3 and TSU-PR1 with standard and investigational agents in SCID mice.
Investigational new drugs 1997;15(2):99-108.
1996: Corbett T H; Valeriote F A; Demchik L; Polin L; Panchapor C; Pugh S; White K; Knight J; Jones J; Jones L; LoRusso P; Foster B; Wiegand R A; Lisow L; Golakoti T; Heltzel C E; Ogino J; Patterson G M; Moore R E
Preclinical anticancer activity of cryptophycin-8.
Journal of experimental therapeutics & oncology 1996;1(2):95-108.
1996: Merisko-Liversidge E; Sarpotdar P; Bruno J; Hajj S; Wei L; Peltier N; Rake J; Shaw J M; Pugh S; Polin L; Jones J; Corbett T; Cooper E; Liversidge G G
Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs.
Pharmaceutical research 1996;13(2):272-8.
1996: LoRusso P M; Demchik L; Foster B; Knight J; Bissery M C; Polin L M; Leopold W R; Corbett T H
Preclinical antitumor activity of CI-994.
Investigational new drugs 1996;14(4):349-56.
1996: Palomino E; Foster B; Kempff M; Corbett T; Wiegand R; Horwitz J; Baker L
Identification and antitumor activity of a reduction product in the murine metabolism of pyrazoloacridine (NSC-366140).
Cancer chemotherapy and pharmacology 1996;38(5):453-8.
1996: Valeriote F; Corbett T; Edelstein M; Baker L
New in vitro screening model for the discovery of antileukemic anticancer agents.
Cancer investigation 1996;14(2):124-41.
1995: Oberlies N H; Jones J L; Corbett T H; Fotopoulos S S; McLaughlin J L
Tumor cell growth inhibition by several Annonaceous acetogenins in an in vitro disk diffusion assay.
Cancer letters 1995;96(1):55-62.
1995: Coughlin S A; Danz D W; Robinson R G; Klingbeil K M; Wentland M P; Corbett T H; Waud W R; Zwelling L A; Altschuler E; Bales E
Mechanism of action and antitumor activity of (S)-10-(2,6-dimethyl-4-pyridinyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7 H- pyridol[1,2,3-de]-[1,4]benzothiazine-6-carboxylic acid (WIN 58161).
Biochemical pharmacology 1995;50(1):111-22.
1995: LoRusso P; Demchik L; Dan M; Polin L; Gross J L; Corbett T H
Comparative efficacy of DMP 840 against mouse and human solid tumor models.
Investigational new drugs 1995;13(3):195-203.
1995: Djuric Z; Corbett T H; Valeriote F A; Heilbrun L K; Baker L H
Detoxification ability and toxicity of quinones in mouse and human tumor cell lines used for anticancer drug screening.
Cancer chemotherapy and pharmacology 1995;36(1):20-6.
1994: Horwitz J P; Massova I; Wiese T E; Besler B H; Corbett T H
Comparative molecular field analysis of the antitumor activity of 9H-thioxanthen-9-one derivatives against pancreatic ductal carcinoma 03.
Journal of medicinal chemistry 1994;37(6):781-6.
1993: Horwitz J P; Massova I; Wiese T E; Wozniak A J; Corbett T H; Sebolt-Leopold J S; Capps D B; Leopold W R
Comparative molecular field analysis of in vitro growth inhibition of L1210 and HCT-8 cells by some pyrazoloacridines.
Journal of medicinal chemistry 1993;36(23):3511-6.
1992: Poplin E A; Corbett T; Flaherty L; Tarasoff P; Redman B G; Valdivieso M; Baker L
Difluorodeoxycytidine (dFdC)--gemcitabine: a phase I study.
Investigational new drugs 1992;10(3):165-70.
1991: Negendank W; Corbett T; Crowley M; Kellogg C
Evidence for a contribution of paramagnetic ions to water proton spin-lattice relaxation in normal and malignant mouse tissues.
Magnetic resonance in medicine : official journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine 1991;18(2):280-93.
1991: Phadtare S; Kessel D; Corbett T H; Renis H E; Court B A; Zimlicka J
Unsaturated and carbocyclic nucleoside analogues: synthesis, antitumor, and antiviral activity.
Journal of medicinal chemistry 1991;34(1):421-9.
1990: LoRusso P M; Aukerman S L; Polin L; Redman B G; Valdivieso M; Biernat L; Corbett T H
Antitumor efficacy of interleukin-2 alone and in combination with adriamycin and dacarbazine in murine solid tumor systems.
Cancer research 1990;50(18):5876-82.
1990: Neelam S S; Bernabei A; Freedland C; Thompson R; Corbett T H; Luk G D
Combination of flavone acetic acid (FAA) with adriamycin, cis-platinum and difluoromethylornithine (DFMO) in vitro against human colon cancer cells.
Investigational new drugs 1990;8(3):263-8.
1990: Mucci-LoRusso P; Polin L; Biernat L A; Valeriote F A; Corbett T H
Activity of datelliptium acetate (NSC 311152; SR 95156A) against solid tumors of mice.
Investigational new drugs 1990;8(3):253-61.
1990: LoRusso P; Wozniak A J; Polin L; Capps D; Leopold W R; Werbel L M; Biernat L; Dan M E; Corbett T H
Antitumor efficacy of PD115934 (NSC 366140) against solid tumors of mice.
Cancer research 1990;50(16):4900-5.
1990: De Neve W; Evelhoch J; Everett C; Simpson N; Bissery M C; Corbett T; Valeriote F
Interaction between flavone acetic acid (LM-975, NSC 349512) and radiation in Glasgow's osteogenic sarcoma in vivo.
International journal of radiation oncology, biology, physics 1990;18(6):1359-65.
1990: DeNeve W; Valeriote F; Tapazoglou E; Everett C; Khatana A; Corbett T
Discrepancy between cytotoxicity and DNA interstrand crosslinking of carboplatin and cisplatin in vivo.
Investigational new drugs 1990;8(1):17-24.
1990: Negendank W G; McCoy L E; Crowley M G; Corbett T H; Schmidt E L
In vitro measurement of tissue vascular space by 19F NMR of a perfluorocarbon blood substitute.
Biomaterials, artificial cells, and artificial organs 1990;18(1):119-23.
1990: Brodfuehrer J; Valeriote F; Chan K; Heilbrun L; Corbett T
Flavone acetic acid and plasma protein binding.
Cancer chemotherapy and pharmacology 1990;27(1):27-32.
1989: Mucci-LoRusso P; Polin L; Bissery M C; Valeriote F; Plowman J; Luk G D; Corbett T H
Activity of batracylin (NSC-320846) against solid tumors of mice.
Investigational new drugs 1989;7(4):295-306.
1989: Corbett T H; Bissery M C; Mucci-LoRusso P; Polin L
5-Fluorouracil containing combinations in murine tumor systems.
Investigational new drugs 1989;7(1):37-49.
1989: Chabot G G; Bissery M C; Corbett T H; Rutkowski K; Baker L H
Pharmacodynamics and causes of dose-dependent pharmacokinetics of flavone-8-acetic acid (LM-975; NSC-347512) in mice.
Cancer chemotherapy and pharmacology 1989;24(1):15-22.
1988: Tapazoglou E; Polin L; Corbett T H; al-Sarraf M
Chemotherapy of the squamous cell lung cancer LC-12 with 5-fluorouracil, cisplatin, carboplatin or iproplatin combinations.
Investigational new drugs 1988;6(4):259-64.
1988: Evelhoch J L; Bissery M C; Chabot G G; Simpson N E; McCoy C L; Heilbrun L K; Corbett T H
Flavone acetic acid (NSC 347512)-induced modulation of murine tumor physiology monitored by in vivo nuclear magnetic resonance spectroscopy.
Cancer research 1988;48(17):4749-55.
1988: Crissman J D; Zarbo R J; Niebylski C D; Corbett T; Weaver D
Flow cytometric DNA analysis of colon adenocarcinomas: a comparative study of preparatory techniques.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 1988;1(3):198-204.
1988: Bissery M C; Valeriote F A; Chabot G G; Crissman J D; Yost C; Corbett T H
Flavone acetic acid (NSC 347512)-induced DNA damage in Glasgow osteogenic sarcoma in vivo.
Cancer research 1988;48(5):1279-85.
1987: Brooks S C; Horwitz J P; Odden D; Corbett T
A-ring substituted estrogens as inhibitors of the MXT transplantable mammary ductal carcinoma.
Cancer research 1987;47(17):4623-9.
1987: Ensley J F; Maciorowski Z; Pietraszkiewicz H; Klemic G; KuKuruga M; Sapareto S; Corbett T; Crissman J
Solid tumor preparation for flow cytometry using a standard murine model.
Cytometry 1987;8(5):479-87.
1987: Pazdur R; Redman B G; Corbett T; Phillips M; Baker L H
Phase I trial of spiromustine (NSC 172112) and evaluation of toxicity and schedule in a murine model.
Cancer research 1987;47(15):4213-7.
1987: Leopold W R; Corbett T H; Griswold D P; Plowman J; Baguley B C
Experimental antitumor activity of the amsacrine analogue CI-921.
Journal of the National Cancer Institute 1987;79(2):343-9.
1987: Evelhoch J L; Keller N A; Corbett T H
Response-specific adriamycin sensitivity markers provided by in vivo 31P nuclear magnetic resonance spectroscopy in murine mammary adenocarcinomas.
Cancer research 1987;47(13):3396-401.
1987: O'Dwyer P J; Shoemaker D; Zaharko D S; Grieshaber C; Plowman J; Corbett T; Valeriote F; King S A; Cradock J; Hoth D F
Flavone acetic acid (LM 975, NSC 347512). A novel antitumor agent.
Cancer chemotherapy and pharmacology 1987;19(1):6-10.
1987: Banning J W; Abramson H N; Wormser H C; Wu J D; Corbett T H
Relative cardiotoxicity and cytotoxicity of anthraquinonyl glucosaminosides.
Cancer chemotherapy and pharmacology 1987;19(3):207-12.
1987: Corbett T H; Valeriote F A; Baker L H
Is the P388 murine tumor no longer adequate as a drug discovery model?
Investigational new drugs 1987;5(1):3-20.
1986: Corbett T H; Bissery M C; Wozniak A; Plowman J; Polin L; Tapazoglou E; Dieckman J; Valeriote F
Activity of flavone acetic acid (NSC-347512) against solid tumors of mice.
Investigational new drugs 1986;4(3):207-20.
1985: Kessel D; Corbett T
Correlations between anthracycline resistance, drug accumulation and membrane glycoprotein patterns in solid tumors of mice.
Cancer letters 1985;28(2):187-93.
1985: Nachtman J P; Roginski E T; Banning J W; Wormser H C; Abramson H N; Corbett T H
DNA binding, cardiac superoxide production and cytotoxicity of daunomycin analogs.
Research communications in chemical pathology and pharmacology 1985;47(1):73-83.
1984: Schabel F M; Griswold D P; Corbett T H; Laster W R
Increasing the therapeutic response rates to anticancer drugs by applying the basic principles of pharmacology.
Cancer 1984;54(6 Suppl):1160-7.
1984: Corbett T H; Roberts B J; Leopold W R; Peckham J C; Wilkoff L J; Griswold D P; Schabel F M
Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice.
Cancer research 1984;44(2):717-26.
1983: Schabel F M; Corbett T H; Griswold D P; Laster W R; Trader M W
Therapeutic activity of mitoxantrone and ametantrone against murine tumors.
Cancer treatment reviews 1983;10 Suppl B():13-21.
1983: Schabel F M; Skipper H E; Trader M W; Laster W R; Griswold D P; Corbett T H
Establishment of cross-resistance profiles for new agents.
Cancer treatment reports 1983;67(10):905-22.
1983: Struck R F; Dykes D J; Corbett T H; Suling W J; Trader M W
Isophosphoramide mustard, a metabolite of ifosfamide with activity against murine tumours comparable to cyclophosphamide.
British journal of cancer 1983;47(1):15-26.
1983: Evanochko W T; Ng T C; Lilly M B; Lawson A J; Corbett T H; Durant J R; Glickson J D
In vivo 31P NMR study of the metabolism of murine mammary 16/C adenocarcinoma and its response to chemotherapy, x-radiation, and hyperthermia.
Proceedings of the National Academy of Sciences of the United States of America 1983;80(2):334-8.
1983: Schabel F M; Griswold D P; Corbett T H; Laster W R
Increasing therapeutic response rates to anticancer drugs by applying the basic principles of pharmacology.
Pharmacology & therapeutics 1983;20(2):283-305.
1982: Evanochko W T; Ng T C; Glickson J D; Durant J R; Corbett T H
Human tumors as examined by in vivo 31P NMR in athymic mice.
Biochemical and biophysical research communications 1982;109(4):1346-52.
1982: Corbett T H; Roberts B J; Trader M W; Laster W R; Griswold D P; Schabel F M
Response of transplantable tumors of mice to anthracenedione derivatives alone and in combination with clinically useful agents.
Cancer treatment reports 1982;66(5):1187-200.
1982: Corbett T H; Leopold W R; Dykes D J; Roberts B J; Griswold D P; Schabel F M
Toxicity and anticancer activity of a new triazine antifolate (NSC 127755).
Cancer research 1982;42(5):1707-15.
1982: Spears C P; Shahinian A H; Moran R G; Heidelberger C; Corbett T H
In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas.
Cancer research 1982;42(2):450-6.
1982: Schabel F M; Skipper H E; Trader M W; Brockman R W; Laster W R; Corbett T H; Griswold D P
Drug control of Ara-C-resistant tumor cells.
Medical and pediatric oncology 1982;10 Suppl 1():125-48.
1981: Griswold D P; Corbett T H; Schabel F M
Clonogenicity and growth of experimental tumors in relation to developing resistance and therapeutic failure.
Cancer treatment reports 1981;65 Suppl 2():51-4.
1981: Corbett T H
Carcinogenesis.
International anesthesiology clinics 1981;19(4):99-120.
1981: Corbett T H; Griswold D P; Roberts B J; Schabel F M
Absence of delayed lethality in mice treated with aclacinomycin A.
Cancer chemotherapy and pharmacology 1981;6(2):161-8.
1980: Simpson-Herren L; Corbett T H; Griswold D P
The cell population kinetics and response to an S-phase specific agent of three transplantable colon tumor lines.
Cell and tissue kinetics 1980;13(6):613-24.
1980: Schabel F M; Corbett T H; Schabel F M
Cell kinetics and the chemotherapy of murine solid tumors.
Antibiotics and chemotherapy 1980;28():28-34.
1980: Schabel F M; Skipper H E; Trader M W; Laster W R; Corbett T H; Griswold D P
Concepts for controlling drug-resistant tumor cells.
European journal of cancer 1980;Suppl 1():199-211.
1979: Schabel F M; Trader M W; Laster W R; Corbett T H; Griswold D P
cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice.
Cancer treatment reports 1979;63(9-10):1459-73.
1979: Corbett T H; Griswold D P; Wolpert M K; Venditti J M; Schabel F M
Design and evaluation of combination chemotherapy trials in experimental animal tumor systems.
Cancer treatment reports 1979;63(5):799-801.
1979: Corbett T H
Pharmacology and toxicology of halogenated anesthetics.
Advances in pharmacology and chemotherapy 1979;16():195-212.
1978: Corbett T H; Griswold D P; Roberts B J; Peckham J C; Schabel F M
Biology and therapeutic response of a mouse mammary adenocarcinoma (16/C) and its potential as a model for surgical adjuvant chemotherapy.
Cancer treatment reports 1978;62(10):1471-88.
1978: Roberts B J; Fife W P; Corbett T H; Schabel F M
Response of five established solid transplantable mouse tumors and one mouse leukemia to hyperbaric hydrogen.
Cancer treatment reports 1978;62(7):1077-9.
1978: Simpson-Herren L; Griswold D P; Corbett T H
Studies of the growth, population kinetics, and host lethality of CD8F mammary adenocarcinoma.
Cancer treatment reports 1978;62(4):519-28.
1978: Corbett T H; Simmons J L; Kawanishi H; Endres J L
EM changes and other toxic effects of firemaster BP-6 (polybrominated biphenyls) in the mouse.
Environmental health perspectives 1978;23():275-81.
1977: Corbett T H; Griswold D P; Roberts B J; Peckham J C; Schabel F M
Evaluation of single agents and combinations of chemotherapeutic agents in mouse colon carcinomas.
Cancer 1977;40(5 Suppl):2660-80.
1977: Sanl B P; Corbett T H
Retinoic acid-binding protein in normal tissues and experimental tumors.
Cancer research 1977;37(1):209-13.
1976: Corbett T H
O.R. exposure--cancer, miscarriages, and birth defects.
Women & health 1976;1(5):11-4.
1976: Corbett T H
Cancer and congenital anomalies associated with anesthetics.
Annals of the New York Academy of Sciences 1976;271():58-66.
1975: Griswold D P; Corbett T H
A colon tumor model for anticancer agent evaluation.
Cancer 1975;36(6 Suppl):2441-4.
1975: Corbett T H; Griswold D P; Roberts B J; Peckham J C; Schabel F M
Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure.
Cancer research 1975;35(9):2434-9.
1975: Corbett T H; Griswold D P; Mayo J G; Laster W R; Schabel F M
Cyclophosphamide-adriamycin combination chemotherapy of transplantable murine tumors.
Cancer research 1975;35(6):1568-73.
1974: Corbett T H; Nettesheim P
Separation of multiple forms of protein-bound metabolites of the carcinogenic hydrocarbons 3-methylcholanthrene and 7,12-dimethylbenz(a)anthracene from several rodent species.
Chemico-biological interactions 1974;8(5):285-96.
1973: Corbett T H; Nettesheim P
Effect of PR-8 viral respiratory infection of benz[a]pyrene hydroxylase activity in BALB/c mice.
Journal of the National Cancer Institute 1973;50(3):779-82.
1970: Corbett T H; Heidelberger C; Dove W F
Determination of the mutagenic activity to bacteriophage T4 of carcinogenic and noncarcinogenic compounds.
Molecular pharmacology 1970;6(6):667-79.

Sign-in to see more